ENDPOINTS NEWS15h
Mer­ck KGaA’s life sci­ence unit is still feel­ing the Covid de­mand de­cline
Merck KGaA reported a 16.6% decline in contract manufacturing due to an unrepeated Covid-19 contract, though overall life ...
bnnbloomberg21h
Merck KGaA Beats Estimates on Boost From Life Science Unit
(Bloomberg) -- Merck KGaA posted earnings that topped estimates as its life science unit recovers from its ...
The Pharma Letter13h
Merck & Co wades into PD-1/VEGF space via deal with LaNova Medicines
Merck & Co has entered into an exclusive global license to develop, manufacture and commercialize LM-299 from China-based ...
Merck KGaA stock falls on weak Q3, soft outlook
Investing.com -- Shares of Merck KGaA (ETR: MRCG) fell over 4% on Thursday following a mixed reception to its third-quarter ...
Merck Announces Emerging Biotech Grant Program Winners
data-text="Merck Announces Emerging Biotech Grant Program Winners" data-link=" Announces Emerging Biotech Grant Program ...
The Pharma Letter14h
Merck KGaA shares slip on cautious outlook
Merck, which previously predicted 2024 sales of between ... data analyses and commentary from our global network of life ...
Germany’s Merck Expects Sales at Lower End of Outlook Range After Third-Quarter Miss
The life-sciences and chemical group said it now expects 2024 net sales in the lower half of its previously expected range of ...